A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refracto...
Saved in:
| Published in | Journal of hematology and oncology Vol. 11; no. 1; pp. 141 - 8 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
20.12.2018
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM).
This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m
. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 10
cells/kg [range, 0.07 to 2.1 × 10
]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group.
At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade ≥ 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached.
LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM.
ClinicalTrials.gov , NCT03090659 ; Registered on March 27, 2017, retrospectively registered. |
|---|---|
| AbstractList | Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM).
This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m
. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 10
cells/kg [range, 0.07 to 2.1 × 10
]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group.
At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade ≥ 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached.
LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM.
ClinicalTrials.gov , NCT03090659 ; Registered on March 27, 2017, retrospectively registered. Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM). This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m.sup.2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 x 10.sup.6 cells/kg [range, 0.07 to 2.1 x 10.sup.6]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group. At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced [greater than or equai to] 1 adverse events (AEs). Grade [greater than or equai to] 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade [greater than or equai to] 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached. LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM. Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Methods This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m.sup.2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 x 10.sup.6 cells/kg [range, 0.07 to 2.1 x 10.sup.6]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group. Results At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced [greater than or equai to] 1 adverse events (AEs). Grade [greater than or equai to] 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade [greater than or equai to] 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached. Conclusions LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM. Trial registration ClinicalTrials.gov, NCT03090659; Registered on March 27, 2017, retrospectively registered Keywords: Chimeric antigen receptor, CAR T, BCMA, Multiple myeloma, Relapsed, Refractory Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Methods This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 106 cells/kg [range, 0.07 to 2.1 × 106]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group. Results At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade ≥ 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached. Conclusions LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM. Trial registration ClinicalTrials.gov, NCT03090659; Registered on March 27, 2017, retrospectively registered Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM).BACKGROUNDChimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM).This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 106 cells/kg [range, 0.07 to 2.1 × 106]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group.METHODSThis ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 106 cells/kg [range, 0.07 to 2.1 × 106]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group.At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade ≥ 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached.RESULTSAt data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade ≥ 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached.LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM.CONCLUSIONSLCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM.ClinicalTrials.gov , NCT03090659 ; Registered on March 27, 2017, retrospectively registered.TRIAL REGISTRATIONClinicalTrials.gov , NCT03090659 ; Registered on March 27, 2017, retrospectively registered. Abstract Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Methods This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 106 cells/kg [range, 0.07 to 2.1 × 106]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group. Results At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade ≥ 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached. Conclusions LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM. Trial registration ClinicalTrials.gov, NCT03090659; Registered on March 27, 2017, retrospectively registered |
| ArticleNumber | 141 |
| Audience | Academic |
| Author | Zhang, Hui Geng, Yan Wang, Xu-Geng Gu, Liu-Fang Zhang, Wang-Gang Yang, Nan Liu, Jie Xu, Yan Wang, Jian-Li He, Ai-Li Zhao, Wan-Hong Shen, Ying Zhang, Ru Zhang, Peng-Yu Wang, Fang-Xia Lei, Bo He, Qian Zhang, Rui-Li Wang, Bai-Yan Wei, Li-Li Zhang, Yi-Lin Li, Zhen-Zhen Cao, Xing-Mei Zhuang, Qiu-Chuan Yang, Yun Bai, Ju Fan, Xiao-Hu Chen, Yin-Xia Li, Zong-Fang |
| Author_xml | – sequence: 1 givenname: Wan-Hong surname: Zhao fullname: Zhao, Wan-Hong – sequence: 2 givenname: Jie surname: Liu fullname: Liu, Jie – sequence: 3 givenname: Bai-Yan surname: Wang fullname: Wang, Bai-Yan – sequence: 4 givenname: Yin-Xia surname: Chen fullname: Chen, Yin-Xia – sequence: 5 givenname: Xing-Mei surname: Cao fullname: Cao, Xing-Mei – sequence: 6 givenname: Yun surname: Yang fullname: Yang, Yun – sequence: 7 givenname: Yi-Lin surname: Zhang fullname: Zhang, Yi-Lin – sequence: 8 givenname: Fang-Xia surname: Wang fullname: Wang, Fang-Xia – sequence: 9 givenname: Peng-Yu surname: Zhang fullname: Zhang, Peng-Yu – sequence: 10 givenname: Bo surname: Lei fullname: Lei, Bo – sequence: 11 givenname: Liu-Fang surname: Gu fullname: Gu, Liu-Fang – sequence: 12 givenname: Jian-Li surname: Wang fullname: Wang, Jian-Li – sequence: 13 givenname: Nan surname: Yang fullname: Yang, Nan – sequence: 14 givenname: Ru surname: Zhang fullname: Zhang, Ru – sequence: 15 givenname: Hui surname: Zhang fullname: Zhang, Hui – sequence: 16 givenname: Ying surname: Shen fullname: Shen, Ying – sequence: 17 givenname: Ju surname: Bai fullname: Bai, Ju – sequence: 18 givenname: Yan surname: Xu fullname: Xu, Yan – sequence: 19 givenname: Xu-Geng surname: Wang fullname: Wang, Xu-Geng – sequence: 20 givenname: Rui-Li surname: Zhang fullname: Zhang, Rui-Li – sequence: 21 givenname: Li-Li surname: Wei fullname: Wei, Li-Li – sequence: 22 givenname: Zong-Fang surname: Li fullname: Li, Zong-Fang – sequence: 23 givenname: Zhen-Zhen surname: Li fullname: Li, Zhen-Zhen – sequence: 24 givenname: Yan surname: Geng fullname: Geng, Yan – sequence: 25 givenname: Qian surname: He fullname: He, Qian – sequence: 26 givenname: Qiu-Chuan surname: Zhuang fullname: Zhuang, Qiu-Chuan – sequence: 27 givenname: Xiao-Hu surname: Fan fullname: Fan, Xiao-Hu – sequence: 28 givenname: Ai-Li surname: He fullname: He, Ai-Li – sequence: 29 givenname: Wang-Gang surname: Zhang fullname: Zhang, Wang-Gang |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30572922$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1k9tu1DAQhiNURA_wANwgS0iIi6bYOTj2TaXtikOlIiRUrq2J42xcOXawHdA-Gm-H022hW4FykWjmn2_sPzPH2YF1VmXZS4LPCGH0XSAlruocE5ZjykhOn2RHpKlpzpqiOHjwfZgdh3CDMSW8wM-ywxLXTcGL4ij7tULTAEEhcorcpGxuoFUGhTh3W-R6dLVefc0vSvb5FAGSgx6V1xKBjXqjLPJKqik6j66RVMagOCgP0xZ1OmWi6hBsQNsQ0cUuP0KcPUTt7D3iFGmLphRSNgb0U8chQQ1MIRUnrle9B5k6bNE4m6gno9C4VcaN8Dx72oMJ6sXd-yT79uH99fpTfvXl4-V6dZXLmpOYs67FBGPekB4zKqu6bSRUJRRSFoy2neSMVH3bqQZA8TIFW6IayUvMCW6lLE-yyx23c3AjJq9H8FvhQIvbgPMbAT5qaZSoaN13VU1pSVnFZcK1HWsqRThnVYshsc53rGluR9XJdGkPZg-6n7F6EBv3Q9ASF4meAG_vAN59n1WIYtRhsRascnMQBamXXhUpkvT1I-mNm71NViUVZXWxnPOvagPpAtr2LvWVC1Ssaspx09SYJ9XZP1Tp6dSoZRrKXqf4XsGbBwWDAhOH4My8_PqwL3z10JE_VtxPaBI0O4H0LoQ0D0LqeDtC6QjaCILFsgtitwsi7YJYdiE5dpKRR5X38P_X_Abk0wq4 |
| CitedBy_id | crossref_primary_10_1002_cam4_5818 crossref_primary_10_1186_s13046_021_02148_6 crossref_primary_10_3389_fimmu_2020_00888 crossref_primary_10_1016_j_heliyon_2024_e39698 crossref_primary_10_3390_biom11020238 crossref_primary_10_1016_j_intimp_2022_109592 crossref_primary_10_1007_s11654_019_00175_6 crossref_primary_10_2147_OTT_S370880 crossref_primary_10_3389_fimmu_2019_02250 crossref_primary_10_1038_s41417_024_00750_2 crossref_primary_10_1097_PPO_0000000000000506 crossref_primary_10_1177_20406207211019622 crossref_primary_10_1182_bloodadvances_2020002509 crossref_primary_10_1016_S2352_3026_21_00057_0 crossref_primary_10_1111_bjh_19340 crossref_primary_10_1016_j_biopha_2021_112512 crossref_primary_10_3390_cancers12041045 crossref_primary_10_1016_j_jcyt_2024_08_007 crossref_primary_10_1080_14737140_2020_1708721 crossref_primary_10_1111_imr_12988 crossref_primary_10_3390_cancers13184701 crossref_primary_10_1038_s41467_024_47801_8 crossref_primary_10_1080_14712598_2019_1641196 crossref_primary_10_3390_hemato2010007 crossref_primary_10_1080_14737140_2021_1837627 crossref_primary_10_3389_fphar_2020_544754 crossref_primary_10_1016_j_jtha_2024_03_021 crossref_primary_10_3390_hemato2010001 crossref_primary_10_1158_1078_0432_CCR_23_0132 crossref_primary_10_3390_antib8030041 crossref_primary_10_1136_jitc_2022_005091 crossref_primary_10_1007_s00277_020_03970_2 crossref_primary_10_3389_fonc_2020_00636 crossref_primary_10_1016_j_canlet_2022_215949 crossref_primary_10_1097_CJI_0000000000000391 crossref_primary_10_3389_fimmu_2020_620312 crossref_primary_10_3389_fimmu_2022_1079181 crossref_primary_10_1016_j_annonc_2020_10_478 crossref_primary_10_1111_cas_15556 crossref_primary_10_1016_j_annonc_2021_12_003 crossref_primary_10_1186_s12943_019_1092_1 crossref_primary_10_1186_s13045_021_01170_7 crossref_primary_10_2147_CMAR_S510408 crossref_primary_10_1007_s12254_024_00996_4 crossref_primary_10_3389_fimmu_2022_1005800 crossref_primary_10_1007_s40265_022_01697_0 crossref_primary_10_1186_s12967_024_05159_x crossref_primary_10_1007_s40487_022_00186_4 crossref_primary_10_1186_s13287_021_02283_z crossref_primary_10_1038_s41375_021_01269_3 crossref_primary_10_1136_jitc_2022_005678 crossref_primary_10_1080_13543784_2020_1814253 crossref_primary_10_3324_haematol_2022_281339 crossref_primary_10_1080_10428194_2020_1761967 crossref_primary_10_1182_hematology_2020000144 crossref_primary_10_33145_2304_8336_2023_28_65_74 crossref_primary_10_1016_j_chembiol_2020_11_012 crossref_primary_10_1016_j_omto_2023_07_007 crossref_primary_10_1038_s41375_022_01539_8 crossref_primary_10_23736_S0031_0808_20_04121_X crossref_primary_10_1016_j_jtct_2023_06_010 crossref_primary_10_1097_CCO_0000000000000667 crossref_primary_10_3390_cancers12061473 crossref_primary_10_1097_MD_0000000000019739 crossref_primary_10_1097_PPO_0000000000000525 crossref_primary_10_1038_s41408_020_00350_x crossref_primary_10_3390_jcm11092513 crossref_primary_10_1002_ctm2_346 crossref_primary_10_1038_s41408_024_01191_8 crossref_primary_10_1097_CM9_0000000000002476 crossref_primary_10_1007_s00262_024_03913_0 crossref_primary_10_2174_2589977515666230220092125 crossref_primary_10_3389_fimmu_2021_717850 crossref_primary_10_1016_j_slasd_2023_08_008 crossref_primary_10_3389_fonc_2024_1455464 crossref_primary_10_1016_j_critrevonc_2021_103239 crossref_primary_10_3389_fimmu_2024_1476859 crossref_primary_10_3324_haematol_2022_282316 crossref_primary_10_1002_smtd_202401783 crossref_primary_10_1038_s41408_022_00725_2 crossref_primary_10_3324_haematol_2023_283940 crossref_primary_10_1038_s41571_021_00476_2 crossref_primary_10_1016_j_clml_2021_12_003 crossref_primary_10_1080_2162402X_2021_1959102 crossref_primary_10_1158_1078_0432_CCR_19_2111 crossref_primary_10_2217_fon_2022_1317 crossref_primary_10_1136_jitc_2020_000734 crossref_primary_10_1038_s41568_024_00755_x crossref_primary_10_3389_fimmu_2024_1378944 crossref_primary_10_1080_14712598_2020_1790521 crossref_primary_10_1038_s41375_019_0561_2 crossref_primary_10_1186_s12929_023_00982_8 crossref_primary_10_3389_fimmu_2019_01613 crossref_primary_10_3324_haematol_2019_228577 crossref_primary_10_1016_S1470_2045_24_00094_9 crossref_primary_10_1186_s12967_024_05705_7 crossref_primary_10_1016_j_cellimm_2019_103964 crossref_primary_10_1182_blood_2022018905 crossref_primary_10_1016_j_biopha_2022_113919 crossref_primary_10_1080_17474086_2022_2084068 crossref_primary_10_1016_j_hoc_2023_12_004 crossref_primary_10_1038_s41576_021_00329_9 crossref_primary_10_1186_s13045_020_00980_5 crossref_primary_10_3389_fimmu_2022_864868 crossref_primary_10_1158_2767_9764_CRC_21_0157 crossref_primary_10_1038_s41375_022_01559_4 crossref_primary_10_1111_ejh_13426 crossref_primary_10_1186_s13287_021_02510_7 crossref_primary_10_1186_s40779_021_00302_x crossref_primary_10_1136_jitc_2021_002866 crossref_primary_10_1182_blood_2021012811 crossref_primary_10_1038_s41573_021_00175_8 crossref_primary_10_1186_s12885_021_09102_x crossref_primary_10_1186_s13045_023_01408_6 crossref_primary_10_1200_JCO_21_01676 crossref_primary_10_1038_s41467_022_32960_3 crossref_primary_10_3389_fonc_2020_608916 crossref_primary_10_1016_j_clinbiochem_2021_04_002 crossref_primary_10_1016_j_str_2021_11_006 crossref_primary_10_2147_ITT_S240886 crossref_primary_10_1016_j_jacc_2019_10_038 crossref_primary_10_1182_bloodadvances_2020002393 crossref_primary_10_1186_s40364_020_00192_6 crossref_primary_10_1002_ijc_33002 crossref_primary_10_17925_OHR_2021_16_2_111 crossref_primary_10_3389_fonc_2019_01529 crossref_primary_10_1007_s00432_022_04547_4 crossref_primary_10_1038_s41409_020_01023_w crossref_primary_10_1111_bjh_17805 crossref_primary_10_1007_s00108_021_01043_8 crossref_primary_10_1038_s41392_023_01521_5 crossref_primary_10_1111_sji_12910 crossref_primary_10_1016_j_clml_2019_03_025 crossref_primary_10_3390_ijms21228655 crossref_primary_10_1186_s12943_022_01561_5 crossref_primary_10_1186_s13045_019_0823_5 crossref_primary_10_1200_JCO_22_00690 crossref_primary_10_1146_annurev_pharmtox_031720_102211 crossref_primary_10_3389_fimmu_2021_755866 crossref_primary_10_3390_ijms252212201 crossref_primary_10_3390_ph17081025 crossref_primary_10_1056_NEJMoa1817226 crossref_primary_10_1111_bjh_17235 crossref_primary_10_3390_cells9030601 crossref_primary_10_1038_s41571_020_0427_6 crossref_primary_10_1097_PPO_0000000000000379 crossref_primary_10_3389_fimmu_2020_608485 crossref_primary_10_1016_j_exphem_2022_04_007 crossref_primary_10_3390_cancers13143534 crossref_primary_10_1038_s41392_022_01278_3 crossref_primary_10_1200_JOP_19_00244 crossref_primary_10_3389_fonc_2021_783703 crossref_primary_10_22270_jddt_v14i6_6601 crossref_primary_10_3389_fonc_2021_755584 crossref_primary_10_3389_fonc_2020_01362 crossref_primary_10_1111_imr_12774 crossref_primary_10_3389_fonc_2020_01243 crossref_primary_10_3390_cancers14174249 crossref_primary_10_7889_tct_23_002 crossref_primary_10_3389_fgene_2019_00740 crossref_primary_10_3324_haematol_2022_281772 crossref_primary_10_1016_j_jcyt_2022_11_001 crossref_primary_10_1080_14712598_2021_1872540 crossref_primary_10_1097_CM9_0000000000002549 crossref_primary_10_1186_s12967_024_05772_w crossref_primary_10_1016_j_beha_2020_101141 crossref_primary_10_1182_hematology_2019000370 crossref_primary_10_1111_imr_12768 crossref_primary_10_3389_fimmu_2020_577027 crossref_primary_10_1158_2643_3230_BCD_20_0227 crossref_primary_10_1136_bmj_m3176 crossref_primary_10_1016_j_soncn_2023_151505 crossref_primary_10_1002_cam4_3624 crossref_primary_10_3389_fimmu_2023_1101495 crossref_primary_10_3390_biom10101387 crossref_primary_10_3389_fimmu_2023_1012841 crossref_primary_10_3390_cancers14246106 crossref_primary_10_25259_Cytojournal_64_2023 crossref_primary_10_1182_bloodadvances_2024014345 crossref_primary_10_3390_cancers16081599 crossref_primary_10_3390_ijms20051248 crossref_primary_10_1002_ajh_26379 crossref_primary_10_1097_MOH_0000000000000614 crossref_primary_10_1038_s43018_021_00241_5 crossref_primary_10_3390_pharmaceutics17030303 crossref_primary_10_1007_s40487_023_00230_x crossref_primary_10_1080_1744666X_2024_2444673 crossref_primary_10_1136_jitc_2020_000927 crossref_primary_10_1038_s41392_021_00868_x crossref_primary_10_1186_s13045_020_00862_w crossref_primary_10_3390_cells9040983 crossref_primary_10_3389_fimmu_2022_839097 crossref_primary_10_1186_s13045_019_0819_1 crossref_primary_10_1016_j_bbmt_2020_07_019 crossref_primary_10_2217_fon_2020_0521 crossref_primary_10_3389_fimmu_2023_1063838 crossref_primary_10_3389_fimmu_2023_1243997 crossref_primary_10_3390_cancers13153912 crossref_primary_10_1016_j_intimp_2022_109442 crossref_primary_10_1038_s41573_024_01053_9 crossref_primary_10_1002_cpt_2631 crossref_primary_10_1016_j_jmoldx_2023_06_002 crossref_primary_10_1186_s13045_024_01530_z crossref_primary_10_3390_ijms24065994 crossref_primary_10_1186_s13045_022_01301_8 crossref_primary_10_1007_s11864_025_01290_z crossref_primary_10_3390_cancers15092633 crossref_primary_10_1002_acg2_72 crossref_primary_10_1016_j_jtct_2024_11_012 crossref_primary_10_1016_j_addr_2022_114301 crossref_primary_10_1038_s41423_020_00555_x crossref_primary_10_1002_cpt_3057 crossref_primary_10_1038_s41408_023_00929_0 crossref_primary_10_1073_pnas_1819745116 crossref_primary_10_1002_cpt_1674 crossref_primary_10_1016_j_jbi_2023_104367 crossref_primary_10_1186_s12943_022_01669_8 crossref_primary_10_1177_10932607241301699 crossref_primary_10_3389_fonc_2022_901266 crossref_primary_10_1002_phar_2414 crossref_primary_10_1007_s00441_021_03479_8 crossref_primary_10_1111_jcmm_17029 crossref_primary_10_1016_j_retram_2021_103320 crossref_primary_10_3390_hemato2040043 crossref_primary_10_3389_fimmu_2022_991092 crossref_primary_10_3390_cancers13122853 crossref_primary_10_3390_cells11030410 crossref_primary_10_1002_cti2_70022 crossref_primary_10_1182_bloodadvances_2021005020 crossref_primary_10_1016_S0140_6736_21_00933_8 crossref_primary_10_1200_EDBK_320085 crossref_primary_10_3390_pharmaceutics12020194 crossref_primary_10_1002_ajh_25428 crossref_primary_10_3389_fimmu_2020_00482 crossref_primary_10_1038_s41408_021_00441_3 crossref_primary_10_1007_s10555_024_10219_1 crossref_primary_10_3389_fimmu_2022_822004 crossref_primary_10_3390_cancers15061791 crossref_primary_10_1186_s13046_022_02540_w crossref_primary_10_1007_s00277_023_05444_7 crossref_primary_10_1158_1078_0432_CCR_20_3600 crossref_primary_10_1038_s41467_019_14119_9 crossref_primary_10_1186_s13045_020_00962_7 crossref_primary_10_7759_cureus_80068 crossref_primary_10_1016_j_beha_2021_101306 crossref_primary_10_1016_j_ymthe_2020_10_023 crossref_primary_10_3389_fphar_2022_950923 crossref_primary_10_1016_j_drudis_2019_11_008 crossref_primary_10_1111_bjh_19960 crossref_primary_10_1097_HS9_0000000000000350 crossref_primary_10_1002_hem3_70054 crossref_primary_10_3390_jcm9072166 crossref_primary_10_1038_s41375_020_0930_x crossref_primary_10_1016_j_clim_2022_109168 crossref_primary_10_1002_acg2_93 crossref_primary_10_1038_s41420_024_01818_6 crossref_primary_10_1186_s40364_020_0182_y crossref_primary_10_1002_ijc_34609 crossref_primary_10_1177_2040620719854171 crossref_primary_10_1186_s12885_023_11753_x crossref_primary_10_1038_s41409_021_01226_9 crossref_primary_10_1136_jitc_2022_005145 crossref_primary_10_1158_1078_0432_CCR_21_2031 crossref_primary_10_1200_JCO_20_01738 crossref_primary_10_1016_S1470_2045_19_30788_0 crossref_primary_10_1158_1078_0432_CCR_20_2188 crossref_primary_10_3389_fimmu_2022_954804 crossref_primary_10_3389_fonc_2025_1494986 crossref_primary_10_1177_2515135520927164 crossref_primary_10_1182_blood_2019004176 crossref_primary_10_1186_s13045_020_01001_1 crossref_primary_10_1111_liv_14771 crossref_primary_10_17650_2782_3202_2024_4_4_53_64 crossref_primary_10_1038_s41375_020_0734_z crossref_primary_10_3390_ijms222212126 crossref_primary_10_3390_life14040461 crossref_primary_10_1038_s41571_023_00754_1 crossref_primary_10_1016_j_ajpath_2024_04_002 crossref_primary_10_3390_curroncol30110705 crossref_primary_10_3892_etm_2023_12170 crossref_primary_10_1111_imm_13861 crossref_primary_10_1016_j_bcp_2019_06_002 crossref_primary_10_1080_14712598_2021_1857361 crossref_primary_10_1007_s12185_022_03365_1 crossref_primary_10_1016_j_jcyt_2024_02_024 crossref_primary_10_1016_S2152_2650_21_01250_7 crossref_primary_10_1186_s40364_022_00417_w crossref_primary_10_3389_fimmu_2022_886546 crossref_primary_10_1007_s12032_024_02491_6 crossref_primary_10_1016_j_clml_2021_06_003 crossref_primary_10_1111_bjh_16550 crossref_primary_10_1186_s40364_022_00371_7 crossref_primary_10_3324_haematol_2022_280629 crossref_primary_10_3390_cancers15245738 crossref_primary_10_1016_j_retram_2023_103378 crossref_primary_10_1007_s11684_021_0904_z crossref_primary_10_1016_j_blre_2020_100695 crossref_primary_10_1038_s41392_019_0070_9 crossref_primary_10_1016_j_beha_2021_101287 crossref_primary_10_1080_19420862_2020_1807721 crossref_primary_10_1016_j_critrevonc_2022_103782 crossref_primary_10_1182_bloodadvances_2022008798 crossref_primary_10_3389_fimmu_2022_832645 crossref_primary_10_1126_scitranslmed_aaz3339 crossref_primary_10_3390_biom13111629 crossref_primary_10_12677_ACM_2023_1361478 crossref_primary_10_1111_ejh_13380 crossref_primary_10_3389_fbioe_2022_797440 crossref_primary_10_1186_s13045_022_01296_2 crossref_primary_10_1186_s13046_021_02214_z crossref_primary_10_1136_bmj_2021_068956 crossref_primary_10_3390_vaccines11111721 crossref_primary_10_3389_fimmu_2020_01128 crossref_primary_10_1016_j_clml_2023_01_017 crossref_primary_10_1093_jnci_djaf006 crossref_primary_10_1007_s11899_019_0498_6 crossref_primary_10_3389_fonc_2023_1124198 crossref_primary_10_3390_cancers11122009 crossref_primary_10_1016_j_bbmt_2020_04_016 crossref_primary_10_3389_fneur_2024_1392831 crossref_primary_10_3390_hemato5020014 crossref_primary_10_3390_hemato5020015 crossref_primary_10_3390_cancers16193288 crossref_primary_10_6004_jnccn_2022_0020 crossref_primary_10_3390_cancers14174082 crossref_primary_10_1007_s00277_021_04599_5 crossref_primary_10_1186_s12943_022_01663_0 crossref_primary_10_2217_fon_2021_1090 crossref_primary_10_3390_ijms21155192 crossref_primary_10_1038_s41423_024_01153_x crossref_primary_10_12677_ACM_2022_12111462 crossref_primary_10_2147_ITT_S306103 crossref_primary_10_1158_1535_7163_MCT_21_0552 crossref_primary_10_1186_s13256_022_03636_9 crossref_primary_10_3389_fimmu_2021_670286 crossref_primary_10_3390_biom12091303 crossref_primary_10_1016_j_jconrel_2020_08_021 crossref_primary_10_1097_MD_0000000000025784 crossref_primary_10_1080_17460441_2024_2319672 crossref_primary_10_1007_s11899_021_00639_z crossref_primary_10_1007_s12254_020_00571_7 crossref_primary_10_1111_sji_13273 crossref_primary_10_1136_jitc_2020_001511 crossref_primary_10_2174_0109298673268932230920063933 crossref_primary_10_1016_j_bcp_2020_114051 crossref_primary_10_1080_14737140_2020_1828071 crossref_primary_10_3390_cancers13235886 crossref_primary_10_3389_fonc_2023_1257175 crossref_primary_10_1080_07853890_2021_1970218 crossref_primary_10_1186_s40164_024_00542_2 crossref_primary_10_5935_2526_8732_20240443 crossref_primary_10_1016_j_clml_2020_06_015 crossref_primary_10_1080_10428194_2022_2030476 crossref_primary_10_1111_ejh_13840 crossref_primary_10_1038_s41392_021_00764_4 crossref_primary_10_3390_jcm10184088 crossref_primary_10_1007_s00262_024_03688_4 crossref_primary_10_1016_j_phrs_2024_107158 crossref_primary_10_1182_bloodadvances_2023010032 crossref_primary_10_3389_fimmu_2021_632937 crossref_primary_10_1016_j_jcyt_2021_05_007 crossref_primary_10_3390_cancers12123576 crossref_primary_10_1002_cyto_b_22099 crossref_primary_10_1097_COC_0000000000000669 crossref_primary_10_3390_ijms24010645 crossref_primary_10_1038_s41375_019_0669_4 crossref_primary_10_1182_bloodadvances_2022007210 crossref_primary_10_1186_s13045_021_01084_4 crossref_primary_10_1200_JCO_19_02657 crossref_primary_10_1182_bloodadvances_2024014982 crossref_primary_10_3389_fimmu_2024_1502936 crossref_primary_10_1080_17474086_2019_1624158 crossref_primary_10_1177_20406207241275797 crossref_primary_10_1038_s41467_023_44648_3 crossref_primary_10_1182_blood_2020008936 crossref_primary_10_1038_s41392_023_01686_z crossref_primary_10_1093_cei_uxae043 crossref_primary_10_23736_S0031_0808_20_04146_4 crossref_primary_10_1186_s40364_019_0178_7 crossref_primary_10_3171_2021_11_FOCUS21590 crossref_primary_10_1080_10428194_2023_2276676 crossref_primary_10_3390_cancers14133230 |
| Cites_doi | 10.1056/NEJMra1011442 10.1056/NEJMoa1506348 10.1200/JCO.2018.36.15_suppl.8007 10.1200/JCO.2007.14.1853 10.1038/bcj.2014.55 10.1182/blood-2010-10-299487 10.1056/NEJMoa1707447 10.1182/blood-2014-05-552729 10.1056/NEJMoa1709866 10.1200/JCO.2009.27.9158 10.1016/j.blre.2008.07.003 10.1002/ajh.23731 10.1038/sj.leu.2404284 10.1086/605664 10.1182/blood-2003-06-2043 10.1016/j.ccell.2017.02.002 10.1016/S1470-2045(14)70442-5 10.1182/blood-2016-04-711903 10.1056/NEJMoa0801479 10.1200/JCO.2018.77.8084 10.1038/leu.2011.196 10.1056/NEJMoa1407222 10.1200/JCO.2017.35.15_suppl.LBA3001 10.1158/1078-0432.CCR-12-2422 10.1056/NEJMoa1505654 10.1016/S0140-6736(15)01120-4 10.1182/blood-2010-02-268862 10.1111/j.1365-2141.2012.09241.x |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2018 |
| Copyright_xml | – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13045-018-0681-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central Database Suite (ProQuest) ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_465fd456636849ce93bd874e19984b0a PMC6302465 A569077509 30572922 10_1186_s13045_018_0681_6 |
| Genre | Multicenter Study Clinical Trial, Phase I Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: ; – fundername: ; grantid: YJZDJH201601 – fundername: ; grantid: 2018ZDXM-SF-039 – fundername: ; grantid: 2018SF-002 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M CGR CUY CVF ECM EIF NPM PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c591t-8db0100971f086c45b7ca43a2cc286bdc9814fbde7aae93c28b1e7c930910bcc3 |
| IEDL.DBID | 7X7 |
| ISSN | 1756-8722 |
| IngestDate | Wed Aug 27 01:30:43 EDT 2025 Thu Aug 21 13:58:19 EDT 2025 Fri Jul 11 10:00:36 EDT 2025 Fri Jul 25 22:36:23 EDT 2025 Tue Jun 17 22:12:02 EDT 2025 Tue Jun 10 21:08:48 EDT 2025 Thu May 22 21:25:27 EDT 2025 Thu Apr 03 07:10:01 EDT 2025 Tue Jul 01 04:23:13 EDT 2025 Thu Apr 24 22:57:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Refractory BCMA Chimeric antigen receptor CAR T Relapsed Multiple myeloma |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c591t-8db0100971f086c45b7ca43a2cc286bdc9814fbde7aae93c28b1e7c930910bcc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2168525663?pq-origsite=%requestingapplication% |
| PMID | 30572922 |
| PQID | 2168525663 |
| PQPubID | 54946 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_465fd456636849ce93bd874e19984b0a pubmedcentral_primary_oai_pubmedcentral_nih_gov_6302465 proquest_miscellaneous_2159984412 proquest_journals_2168525663 gale_infotracmisc_A569077509 gale_infotracacademiconefile_A569077509 gale_healthsolutions_A569077509 pubmed_primary_30572922 crossref_citationtrail_10_1186_s13045_018_0681_6 crossref_primary_10_1186_s13045_018_0681_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-20 |
| PublicationDateYYYYMMDD | 2018-12-20 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2018 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | SV Rajkumar (681_CR23) 2014; 15 JL Harousseau (681_CR2) 2010; 28 HM Lokhorst (681_CR4) 2015; 373 S Lonial (681_CR6) 2016; 387 A Seckinger (681_CR14) 2017; 31 SL Maude (681_CR17) 2018; 378 J Lu (681_CR30) 2014; 4 JN Brudno (681_CR20) 2018; 36 S Lonial (681_CR5) 2015; 373 K Kim (681_CR29) 2014; 89 681_CR24 F Fan (681_CR22) 2017; 35 SK Kumar (681_CR3) 2012; 26 PG Richardson (681_CR9) 2010; 116 AJ Novak (681_CR12) 2004; 103 RO Carpenter (681_CR11) 2013; 19 N Raje (681_CR21) 2018; 36 SA Ali (681_CR31) 2016; 128 A Palumbo (681_CR7) 2009; 23 SV Rajkumar (681_CR27) 2011; 117 SL Maude (681_CR16) 2014; 371 BG Durie (681_CR26) 2006; 20 SS Neelapu (681_CR18) 2017; 377 681_CR19 M Nucci (681_CR28) 2009; 49 SV Rajkumar (681_CR8) 2008; 26 681_CR15 DW Lee (681_CR25) 2014; 124 A Palumbo (681_CR1) 2011; 364 E Sanchez (681_CR13) 2012; 158 JF San Miguel (681_CR10) 2008; 359 |
| References_xml | – volume: 364 start-page: 1046 issue: 11 year: 2011 ident: 681_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMra1011442 – volume: 373 start-page: 1207 issue: 13 year: 2015 ident: 681_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa1506348 – volume: 36 start-page: 8007 year: 2018 ident: 681_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.8007 – volume: 26 start-page: 2171 issue: 13 year: 2008 ident: 681_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.1853 – ident: 681_CR24 – volume: 4 start-page: e239 year: 2014 ident: 681_CR30 publication-title: Blood Cancer J doi: 10.1038/bcj.2014.55 – volume: 117 start-page: 4691 issue: 18 year: 2011 ident: 681_CR27 publication-title: Blood doi: 10.1182/blood-2010-10-299487 – volume: 377 start-page: 2531 issue: 26 year: 2017 ident: 681_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMoa1707447 – volume: 124 start-page: 188 issue: 2 year: 2014 ident: 681_CR25 publication-title: Blood doi: 10.1182/blood-2014-05-552729 – volume: 378 start-page: 439 issue: 5 year: 2018 ident: 681_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa1709866 – volume: 28 start-page: 4621 issue: 30 year: 2010 ident: 681_CR2 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.9158 – volume: 23 start-page: 87 issue: 2 year: 2009 ident: 681_CR7 publication-title: Blood Rev doi: 10.1016/j.blre.2008.07.003 – volume: 89 start-page: 751 issue: 7 year: 2014 ident: 681_CR29 publication-title: Am J Hematol doi: 10.1002/ajh.23731 – ident: 681_CR15 – volume: 20 start-page: 1467 issue: 9 year: 2006 ident: 681_CR26 publication-title: Leukemia doi: 10.1038/sj.leu.2404284 – volume: 49 start-page: 1211 issue: 8 year: 2009 ident: 681_CR28 publication-title: Clin Infect Dis doi: 10.1086/605664 – ident: 681_CR19 – volume: 103 start-page: 689 issue: 2 year: 2004 ident: 681_CR12 publication-title: Blood doi: 10.1182/blood-2003-06-2043 – volume: 31 start-page: 396 issue: 3 year: 2017 ident: 681_CR14 publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.02.002 – volume: 15 start-page: e538 issue: 12 year: 2014 ident: 681_CR23 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70442-5 – volume: 128 start-page: 1688 issue: 13 year: 2016 ident: 681_CR31 publication-title: Blood doi: 10.1182/blood-2016-04-711903 – volume: 359 start-page: 906 issue: 9 year: 2008 ident: 681_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa0801479 – volume: 36 start-page: 2267 issue: 22 year: 2018 ident: 681_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.77.8084 – volume: 26 start-page: 149 issue: 1 year: 2012 ident: 681_CR3 publication-title: Leukemia doi: 10.1038/leu.2011.196 – volume: 371 start-page: 1507 issue: 16 year: 2014 ident: 681_CR16 publication-title: N Engl J Med doi: 10.1056/NEJMoa1407222 – volume: 35 start-page: LBA3001 issue: 18 year: 2017 ident: 681_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.LBA3001 – volume: 19 start-page: 2048 issue: 8 year: 2013 ident: 681_CR11 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-2422 – volume: 373 start-page: 621 issue: 7 year: 2015 ident: 681_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa1505654 – volume: 387 start-page: 1551 issue: 10027 year: 2016 ident: 681_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(15)01120-4 – volume: 116 start-page: 679 issue: 5 year: 2010 ident: 681_CR9 publication-title: Blood doi: 10.1182/blood-2010-02-268862 – volume: 158 start-page: 727 issue: 6 year: 2012 ident: 681_CR13 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2012.09241.x |
| SSID | ssj0061920 |
| Score | 2.625977 |
| Snippet | Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M,... Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of... Abstract Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 141 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Antigen receptors, T cell Antigens Aphasia Aspartate aminotransferase B-Cell Maturation Antigen - metabolism BCMA Blood cancer Cancer CAR T Care and treatment Cellular therapy Chimeric antigen receptor Chimeric antigen receptors Cyclophosphamide Cytokines Epitopes Female Genetic aspects Health risk assessment Hematology Humans Leukemia Leukopenia Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Male Medical prognosis Middle Aged Minimal residual disease Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Neurotoxicity Oncology Patients Physiological aspects Receptors Receptors, Chimeric Antigen - metabolism Refractory Relapsed Remission Induction Safety Studies T cells Thrombocytopenia Working groups Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9swEBZlD6WX0ne93bZTKBRKzEa2JMvHZOmylKaHsgt7E5IsN4HECZvsIT-t_64zsh1iCu2lV2ts5JnRPCTNN4x9FLrCVSPyFFOvkIray7Qcy3HKnbJ5YVWmORUKz76rqxvx9VbeHrX6ojthLTxwy7hzoWRdoZdXudKi9KHMXaULEag2TLhxDI3Q5_XJVGuDKSvozzC5VudbTgeCmDZrarLCUzXwQhGs_0-TfOSThvcljxzQ5RP2uIscYdLO-Cl7EJpn7OGsOxt_zn5NYDNHnwR8BNQTK0X5hiVE_FhY1_DtYvIjneZ6NgILfr6IRzWAjCU8TkDDFzaYf8M10F4-tHVZe2hdXqjA_rQLDCVh2o6vCBA0SrX_xAgWDXQwrVug_V2gQpnNFl_G7yIP7mJvnz30lxhhtQ_L9cq-YDeXX64vrtKuMUPqZcl3qa4cpnGEPlVjRuSFdIW3IreZ95lWrvKl5qJ2VSisRYHhQ8dD4cucghPnff6SnTTrJrxmIMuxzRyGEagvota5LdDIFMEqTd5b8YSNe0EZ36GWU_OMpYnZi1amla1B2RqSrVEJ-3x4ZdNCdvyNeErSPxAS2nZ8gDpoOh00_9LBhL0n3TFt6erBZpiJpL0HiskS9ilSkNXA6XvbFT8gEwh_a0B5NqDE1e6Hw71-ms7abE3GlZYZzS9hHw7D9CbdoGvC-p5oJM1W8Cxhr1p1Pvw02nzMsTIcKQaKPuDKcKRZzCMWucoxyFPy9H-w8Q17lNES5Rna7jN2sru7D28x5Nu5d3F1_wY2wFIj priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1da9swUHQdjL2Mfc9dt91gMBjxFtmSLD-MkZSVMpY9jAb6JmRZbgKJkyUpND9t_253_qJmpa_WyUj3fZLujrEPQucoNSIOMfTyoSicDNOhHIY8UzZOrIo0p0ThyS91NhU_LuTFAWvbWzUI3N4a2lE_qelm8fn6z_4bCvzXSuC1-rLldN2HQbGmFio8VPfYfTRMCTU0mIjuUoFChfZi89ZpPdNUVfD_X0_fMFT9R5Q3rNLpY_aocSdhVNP_CTvw5VP2YNJcmD9jf0ewnqGhAj4A2liIRPcLqIrKwqqAnyej3-E41pMBWHCzeXV_A4htKtIJqA39GoNyOAc64Ic6WWsPtR30OdhLO0f_Esb1-JKqhFakbn8xgHkJTe3WLdChL1D2zHqLk_G_iINN1fBnD-3LRlju_WK1tM_Z9PT7-clZ2HRrCJ1M-S7UeYaxHZWkKjBMckJmibMitpFzkVZZ7lLNRZHlPrHWpzF-zLhPXBqTx5I5F79gh-Wq9K8YyHRoowxJiEwkCh3bBDVP4q3SZNIVD9iwJZRxTSlz6qixMFVIo5WpaWuQtoZoa1TAPnVT1nUdj7uAx0T9DpBKcFcfVptL00i0EUoWObqfKlZapA63lOU6EZ6SFkU2tAF7R7xj6nzWTpGYkaQDCXLUAvaxgiDmxuU722REIBKoKFcP8rgHiSrA9Ydb_jStBJmIKy0jWl_A3nfDNJOe1ZV-dUUwklYreBSwlzU7d5tGQ4CBV4QjSY_Re1jpj5TzWVWgXMXo-Sl5dPeyXrOHEQkfj1BVH7PD3ebKv0EPb5e9reT2H3_hTWk priority: 102 providerName: Scholars Portal |
| Title | A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30572922 https://www.proquest.com/docview/2168525663 https://www.proquest.com/docview/2159984412 https://pubmed.ncbi.nlm.nih.gov/PMC6302465 https://doaj.org/article/465fd456636849ce93bd874e19984b0a |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1da9swUGwtjL2Mfc9bl91gMBg1jWxZlp-GU1pKWMroWsibkGW5CSR2lqQP-Wn7d7uzHa9m0JcErJORdd8n3R1jX4TKkWtE6KPr5XxR2MhPhtHQ55k0YWxkoDglCk8u5cWNGE-jaRtw27TXKvcysRbUeWUpRn4ScKki1M8y_L767VPXKDpdbVtoPGaHVLqMqDqedg4X-Qb7k0yu5MmG07EgOs-KWq1wX_Z0UV2y_3_BfE8z9W9N3lND58_Zs9Z-hLRB-Av2yJUv2ZNJe0L-iv1JYTVDzQT8GKgzlo9Ydguoq8hCVcCP0_TKH4VqcgwG7GxeH9gAbi9V5QQUf26FXjhcA0X0ocnO2kGj-FwO5tbM0aCEUTO-pLKgNW73rziGeQltsdYNUJQXKF1mtcHJ-F7cg3Xd4WcH-6uMsNy5RbU0r9nN-dn16YXftmfwbZTwra_yDJ05qkFVoF9kRZTF1ojQBNYGSma5TRQXRZa72BiXhPgw4y62SUgmSmZt-IYdlFXp3jGIkqEJMjQmkGpEoUITo6iJnZGKdLjkHhvuEaVtW7ucWmgsdO3DKKkb3GrErSbcaumxb92UVVO44yHgEWG_A6Sa2_WDan2rWxbWQkZFLogCpRKJxU_KchULR1mKIhsaj30i2tFNAmsnOXQaUQSCLDOPfa0hSHbg8q1pUyBwE6gKVw_yqAeJPG_7w3v61K3M2eh_HOKxz90wzaR7dKWr7ggmotUKHnjsbUPO3Uej5EdPK8CRuEfovV3pj5TzWV2RXIZo6sno_cPL-sCeBsR8PEDZfMQOtus79xFNum02qPl2wA7TdPxrjP-js8ufV4M6QIK_E6H-AkveT2w |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbhMx0CpFAi6INwuFDhIICWXVeNfr9R4QSgpVSpMeUCrl5nq9ThMpL5JWKD_Fnb9jZl90hdRbrztjy-sZz8PjmWHsvVAZnhoR-uh6OV-MbeQn7ajt81SaMDYyUJwShQensncmvo-i0Q77XeXC0LPKSibmgjpbWrojPwi4VBHqZxl-Wf30qWsURVerFhoFW5y47S902Tafj78ifT8EwdG34WHPL7sK-DZK-KWvshR9ECqdNEZz3oooja0RoQmsDZRMM5soLsZp5mJjXBLix5S72CYhadbU2hDnvcPuouJtk7MXj2oHj3yRKnLKlTzYcApDorOuqLUL92VD9-UtAv5XBNc0YfOV5jW1d_SIPSztVegUDPaY7bjFE3ZvUEbkn7I_HVhNUBMCbwF14vKRq9wM8qq1sBxD_7Dzw--GatACA3YyzQNEgOSkKqCA4tat0OuHIVAEAYpssC0UitZlYC7MFA1Y6BbwOZUhzXmpmqIF0wWUxWE3QLfKQOk5qw0OxnlxD9Z5R6EtVE8nYb51s-XcPGNnt0K452x3sVy4lwyipG2CFI0X5FIxVqGJUbTFzkhFNoPkHmtXhNK2rJVOLTtmOveZlNQFbTXSVhNttfTYp3rIqigUchNyl6hfI1KN7_zDcn2hS5GhhYzGmSCOl0okFn8pzVQsHGVFirRtPLZPvKOLhNlaUulORDceZAl67GOOQbIKl29NmXKBm0BVvxqYew1MlDG2Ca74U5cybqP_nUiPvavBNJLe7S3c8opwIlqt4IHHXhTsXP80ahr07AKExA1Gb-xKE7KYTvIK6DJE01JGr25e1j673xsO-rp_fHrymj0I6CDyAPXCHtu9XF-5N2hOXqZv8zMM7Py2hcZfld2IGg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+phase+1%2C+open-label+study+of+LCAR-B38M%2C+a+chimeric+antigen+receptor+T+cell+therapy+directed+against+B+cell+maturation+antigen%2C+in+patients+with+relapsed+or+refractory+multiple+myeloma&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Wan-Hong%2C+Zhao&rft.au=Jie+Liui-Yan+Wang&rft.au=Yin-Xia%2C+Chen&rft.au=Xing-Mei+Cao&rft.date=2018-12-20&rft.pub=BioMed+Central&rft.eissn=1756-8722&rft.volume=11&rft_id=info:doi/10.1186%2Fs13045-018-0681-6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |